1. < MAC & Bronchiectasis
Profile picture for fedrocker

Rifampin

Posted by fedrocker @tropauer, Jul 24 5:44pm

I heard from my doc about a clinical trial that’s wrapping up, where Rifampin was not given as part of the big 3. The study included only Ethambutol and Azithromycin. Apparently, patients did just as well on the 2 meds. Check with your doc, but my doc is great and worth a post from me here.

Interested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.

Profile picture for blm1007blm1007
blm1007blm1007 | @blm1007blm1007 | Jul 25 2:50pm

Yes, when the doctor mentioned that I consider taking the antibiotics for the Intercellular infection she did not include Rifampin. That was Dr. McShane in 2024. I decided to continue with watchful waiting to this day.
Barbara

REPLY
Profile picture for bayarea58
bayarea58 | @bayarea58 | Jul 25 5:48pm

My specialist at NJH has a different interpretation of the two versus three study. In their opinion, the study showed that three drugs is better than two at conversion, but given the conversion rates of a different study, re Arikayce as a front line drug, the third drug should be Arikayce (rather than rifampin). I have heard other specialists make similar comments recently, i.e. that the recent study results when read together support a new Big 3: azithromycin, ethambutol and Arikayce.

REPLY
2 replies
Profile picture for blm1007blm1007
blm1007blm1007 | @blm1007blm1007 | Jul 26 6:03am
In reply to @bayarea58 "My specialist at NJH has a different interpretation of the two versus three study. In their..." + (show)
Profile picture for bayarea58 @bayarea58

My specialist at NJH has a different interpretation of the two versus three study. In their opinion, the study showed that three drugs is better than two at conversion, but given the conversion rates of a different study, re Arikayce as a front line drug, the third drug should be Arikayce (rather than rifampin). I have heard other specialists make similar comments recently, i.e. that the recent study results when read together support a new Big 3: azithromycin, ethambutol and Arikayce.

Jump to this post

@bayarea58 Yes, the Arikayce was also brought up for me by Dr. McShane and not the Rifampin..
Barbara

REPLY
Profile picture for positivethinking
positivethinking | @positivethinking | Jul 27 8:39am
In reply to @bayarea58 "My specialist at NJH has a different interpretation of the two versus three study. In their..." + (show)
Profile picture for bayarea58 @bayarea58

My specialist at NJH has a different interpretation of the two versus three study. In their opinion, the study showed that three drugs is better than two at conversion, but given the conversion rates of a different study, re Arikayce as a front line drug, the third drug should be Arikayce (rather than rifampin). I have heard other specialists make similar comments recently, i.e. that the recent study results when read together support a new Big 3: azithromycin, ethambutol and Arikayce.

Jump to this post

@bayarea58 good morning -
I’m surprised that the arikayce is used. From what I’ve read it has very dangerous possible side effects especially for people with cardiac issues

REPLY
Please sign in or register to post a reply.